Complement Pathway Inhibitors for Autoimmune Hemolytic Anemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively preventing, reducing the risk of developing, or treating blood disorders such as cold agglutinin hemolytic anemia, autoimmune hemolytic anemia, and thrombocytopenia, as they fail to address the underlying complement activation pathways that contribute to these conditions.
Innovation Solution
Administration of inhibitors targeting the complement pathway, specifically antibodies against C1q, C1r, or C1s, to block the classical complement activation pathway, thereby preventing autoantibody-mediated damage to red blood cells and platelets, while leaving the lectin and alternative pathways intact to maintain normal immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat blood disorders, then treatment is provided, but the underlying complement activation pathways are not addressed, resulting in inadequate therapeutic effect
Solution Approach 1:
The patent extracts and targets the specific complement activation pathway (classical pathway involving C1q, C1r, C1s) that causes blood disorders, separating it from the other complement pathways (lectin and alternative pathways). By using inhibitors that specifically block only the classical pathway, the treatment addresses the root cause of the disease while preserving normal immune function through the other pathways.
Solution Approach 2:
The patent applies local quality by making the treatment pathway-specific rather than blanket inhibition. The inhibitors are designed to selectively block the classical complement pathway (C1q-C1r-C1s) while leaving the lectin and alternative pathways intact, allowing different parts of the complement system to have different functional states - one pathway inhibited, others preserved.
2Object-affected harmful factors
If complement activation is completely inhibited to prevent blood disorders, then hemolysis and thrombocytopenia are reduced, but normal immune function may be compromised
Solution Approach 1:
The patent segments the complement system into three distinct pathways (classical, lectin, alternative) and selectively inhibits only the classical pathway that is pathogenic in blood disorders. This segmentation allows the treatment to address the harmful classical pathway activation while preserving the functional integrity of the lectin and alternative pathways for normal immune defense.
Solution Approach 2:
The treatment applies local quality by creating functional differentiation across the complement pathways - the classical pathway is inhibited to prevent disease, while the lectin and alternative pathways remain active to maintain normal immune function. This localized inhibition strategy preserves overall system adaptability.
3Reliability
If inhibitors block the classical complement pathway to prevent autoantibody-mediated damage, then red blood cell lysis and platelet destruction are arrested, but the mechanism requires specific targeting of multiple complement proteins
Solution Approach 1:
The patent employs preliminary action by blocking the early stage of complement activation at the C1 complex formation (C1q binding to C1r and C1s). By preventing the initial activation step, the treatment stops the cascade before it can produce downstream harmful effects, making the inhibition more efficient and potentially requiring less complex multi-target approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits complement-mediated hemolysis and thrombocytopenia, reducing the risk of developing or treating blood disorders by arresting both intravascular and extravascular red blood cell lysis, and platelet destruction, thereby improving anemia and reducing vascular damage.
Implementation Method 1
Administration of inhibitors targeting the complement pathway, specifically antibodies against C1q, C1r, or C1s, to block the classical complement activation pathway
Data Source
AI summary
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SLE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.